BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance

BIOCRYST PHARMACEUTICALS INC

2025-FY EPS reported $1.21 revenue$874,837,000

Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.
Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).
ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.
Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.
Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.